The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Response Biomedical

Monday Deal Review: September 30, 2013

  Welcome to your Monday Biotech Deal Review for September 30, 2013! There has been a lot of activity in the M&A and finanicngs space the last week.  Hit the break for the full rundown of the weeks’s major biotech news!

Read more of this post

Monday Deal Review: January 28, 2013

Welcome to your Monday Biotech Deal Review for January 28, 2013!  The past week was relatively quiet, but highlights include Sernova’s $2 million private placement and Helix’s closing of their $8.5 million sale of the Rivex division.  Click below to get the whole week’s stories!

Read more of this post

Monday Deal Review: October 15, 2012

Welcome to your Monday Biotech Deal Review for October 15, 2012.  Thanks to Thanksgiving for the Canadians and Columbus day for the Americans out there, this week’s post covers the last two weeks of activity.  Biggest of the weeks’ stories, however, is Aeterna Zentaris Inc.’s $15 million public offering, closing in mid October.  Read onwards to see just how busy this fall the market is shaping up to be. 
Read more of this post

Monday Deal Review: September 31, 2012

Welcome to your Monday Biotech Deal Review for September 31, 2012. This week’s big news is yet another acquisition by Valeant, this time for the U.S rights and inventory of an age-related macular degeneration treatment from QLT Inc. Find more details on this story and others by clicking through.
Read more of this post

Monday Deal Review: August 27, 2012

Welcome to your Monday Biotech Deal Review for August 27, 2012.  Highlights from the previous two weeks include Miraculins Inc’s grant of stock options and distribution agreement with London Drugs, Microbix Biosyetem’s licensing of a thrombolytic biopharmaceutical to Zydus Cadila, and BIOREM’s closing of its private placement.  The Monday Deal Review for August 13, 2012 also marked the last Review authored by Jacob Cawker.  We’d like to thank Jacob for his hard work and years of service! For more about me, please see my Bio, here.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: December 5, 2011

Welcome to your Monday Biotech Deal Review for December 5, 2011.  Some equity investment activity occurred over the previous week, with Resverlogix closing its previously announced $17.5M private placement, Response Biomedical announcing an $8M rights offering, and various other small private placements.  As well, Valeant is going to fund its acquisition of iNova with debt, as summarized further below.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: November 21, 2011

Welcome to your Monday Biotech Deal Review for November 21, 2011.  The week appears to have been dead quiet on the biotech front, with only a handful of items, including the announcement by Response Biomedical of an $8M equity financing by way of a rights offering.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: May 2, 2011

Welcome to your Monday Biotech Deal Review for May 2, 2011.  This review is a double feature from last week’s Easter break.  Plenty happened in the interim, with Angiotech developments, private placements, licensing and other interesting corporate transactions and announcements.  Read on to learn more.  Read more of this post

Monday Deal Review: November 1, 2010

Welcome to the Monday Deal Review for November 1, 2010.  This week’s review contains the news of a possible recapitalization of Angiotech, following its deferral of interest payments on 7.75% Senior Subordinated Notes due October 1, 2010.  Read on to learn more, as well as other happenings from last week’s biotech scene. Read more of this post

Monday Biotech Deal Review: October 25, 2010

Welcome to your weekly review of Canadian biotech deals for October 25, 2010.  Last week’s notable transactions included the Qualifying Transaction of TSXV CPC company CCS Capital Inc. (now known as China Health Labs & Diagnostics Ltd.) and ProMetic’s strategic agreement with Allist Pharmaceuticals Inc., for the commercialization in China of two of ProMetic’s drug candidates.  Read on to learn more about these transactions, as well as the usual assortment of Canadian biotech news. Read more of this post

Monday Biotech Deal Review: August 9, 2010

Catching up from the long weekend last week, we have a full two weeks’ worth of deals to bring you. Highlights include $16.7 million of securities closings, $8.25 million launched; and interesting developments in the Forbes Medi-Tech and Northstar Healthcare acquisitions. Check out what the last two weeks have wrought… after the jump

Monday Biotech Deal Review: July 5, 2010

Not a bad week for deals, considering the holiday weekend in both Canada and the U.S.. Response Biomedical placed a PIPE with OrbiMed funds, CTI did a follow-on round in Zymeworks and LAB Research took an equity line. Plus a companion diagnostic deal from Aeterna, just as I’m planning for Diagnostics Asia in August. The week’s rounded out with $450k from the NRC and a spin-out from Ondine. Read more of this post

Monday Deal Review: May 25, 2009

bignickel1This week’s deal review has a couple of new placements, a couple of new plants, a very interesting claim asserted in Boston, and many, many updates on deals we have previously covered.  Check out the full review after the jump…

Monday Deal Review: May 11, 2009

bignickel1Check out the latest Patheon-JLL developments, a licensing deal that looks like a subcontracting arrangement, a plan of arrangement M&A that looks like a license, and the rest of the Canadian deal info from this past week after the jump…

Monday Deal Review: March 30, 2009

Follow

Get every new post delivered to your Inbox.

Join 130 other followers